{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:31:52Z","timestamp":1770687112287,"version":"3.49.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>The purpose of this study was to explore early changes in patient and family caregiver report of quality of life and family impact during the transitional period of nusinersen use. Communication; family relationships; physical, emotional, social, and cognitive functioning; and daily activities were measured using Pediatric Quality of Life modules (Family Impact Modules and both Patient and Proxy Neuromuscular-Specific Reports) pre- and post-nusinersen exposure. A total of 35 patients with SMA (15 Type 1, 14 Type 2, and 6 Type 3) were grouped according to nusinersen exposure. When analyzed as a whole cross-sectional clinical population, no significant differences were found between the initial and final surveys. Nusinersen therapy was associated with improved communication and emotional functioning in subsets of the population, particularly for patients on maintenance therapy for longer duration. Several unexpected potentially negative findings including increases in family resources and trends towards increases in worry warrant further consideration. Further research is warranted to explore the impact of novel pharmaceuticals on quality of life for children with SMA longitudinally to optimize clinical and psychosocial outcomes.<\/jats:p>","DOI":"10.3390\/children8070604","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T21:16:48Z","timestamp":1626643008000},"page":"604","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy"],"prefix":"10.3390","volume":"8","author":[{"given":"Meaghann S.","family":"Weaver","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital and Medical Center, Omaha, NE 68114, USA"},{"name":"National Center for Ethics in Healthcare, Washington, DC 20420, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Yuroff","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Sund","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Hetzel","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Halanski","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Medical Center, Omaha, NE 68114, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-0037-1603517","article-title":"Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy","volume":"48","author":"Pechmann","year":"2017","journal-title":"Neuropediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1254\/fpj.152.147","article-title":"Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza(R))","volume":"152","author":"Ohmura","year":"2018","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Messina, S., Sframeli, M., Maggi, L., D\u2019Amico, A., Bruno, C., Comi, G., and Mercuri, E. (2021). Spinal muscular atrophy: State of the art and new therapeutic strategies. Neurol. Sci., 1\u201310.","DOI":"10.1007\/s10072-021-05258-3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jpeds.2016.04.062","article-title":"Parents\u2019 Experiences and Wishes at End of Life in Children with Spinal Muscular Atrophy Types I and II","volume":"175","author":"Lovgren","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejpn.2016.08.008","article-title":"Information and treatment decisions in severe spinal muscular atrophy: A parental follow-up","volume":"20","author":"Lovgren","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_8","first-page":"S218","article-title":"Health-related quality of life--an introduction","volume":"13","author":"Khanna","year":"2007","journal-title":"Am. J. Manag. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0883073819900463","article-title":"A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions","volume":"35","author":"Weaver","year":"2020","journal-title":"J. Child Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.nmd.2009.09.009","article-title":"The PedsQL in pediatric patients with Spinal Muscular Atrophy: Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module","volume":"19","author":"Iannaccone","year":"2009","journal-title":"Neuromuscul Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.pediatrneurol.2014.01.037","article-title":"Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic","volume":"50","author":"Kocova","year":"2014","journal-title":"Pediatric Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-2-55","article-title":"The PedsQL Family Impact Module: Preliminary reliability and validity","volume":"2","author":"Varni","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"ref_15","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand. J. Stat."},{"key":"ref_16","unstructured":"Team RC (2019, May 24). A language and environment for statistical computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jpm.2017.0092","article-title":"Proxy-Reported Quality of Life and Family Impact for Children Followed Longitudinally by a Pediatric Palliative Care Team","volume":"21","author":"Weaver","year":"2018","journal-title":"J. Palliat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Italian EAP Working Group. Type I SMA new natural history: Long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/dmcn.14825","article-title":"Parents\u2019 perspectives on nusinersen treatment for children with spinal muscular atrophy","volume":"63","author":"Schroder","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13023-020-01477-7","article-title":"Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: A longitudinal qualitative study","volume":"15","author":"Kiefer","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejpn.2017.10.008","article-title":"Parents\u2019 advice to healthcare professionals working with children who have spinal muscular atrophy","volume":"22","author":"Hjorth","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0883073818822900","article-title":"Parents\u2019 Experiences of Information and Decision Making in the Care of Their Child With Severe Spinal Muscular Atrophy: A Population Survey","volume":"34","author":"Beernaert","year":"2019","journal-title":"J. Child Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0883073818811544","article-title":"Bereaved Parents More Satisfied With the Care Given to Their Child With Severe Spinal Muscular Atrophy Than Nonbereaved","volume":"34","author":"Hjorth","year":"2019","journal-title":"J. Child Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jpc.14959","article-title":"Acknowledging Limits: Statistics and the Child\u2019s Quality of Life in Spinal Muscular Atrophy","volume":"56","author":"Benini","year":"2020","journal-title":"J. Paediatr. Child Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-180330","article-title":"Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy","volume":"6","author":"Pacione","year":"2019","journal-title":"J. Neuromuscul Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e020907","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: An exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar","year":"2018","journal-title":"BMJ Open"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Qian, Y., McGraw, S., Henne, J., Jarecki, J., Hobby, K., and Yeh, W.S. (2015). Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: A qualitative study. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0473-3"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","article-title":"Economic burden of spinal muscular atrophy in the United States: A contemporary assessment","volume":"23","author":"Droege","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.gim.0000215177.28010.6e","article-title":"How does the mode of inheritance of a genetic condition influence families? A study of guilt, blame, stigma, and understanding of inheritance and reproductive risks in families with X-linked and autosomal recessive diseases","volume":"8","author":"James","year":"2006","journal-title":"Genet. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.socscimed.2007.12.022","article-title":"Managing self-responsibility through other-oriented blame: Family accounts of genetic testing","volume":"66","author":"Sarangi","year":"2008","journal-title":"Soc. Sci. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.clinthera.2019.03.012","article-title":"Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community","volume":"41","author":"Cruz","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-020-01593-4","article-title":"Do we always need to treat patients with spinal muscular atrophy? A personal view and experience","volume":"16","author":"Agosto","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: A French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_41","first-page":"179","article-title":"Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single Center","volume":"52","author":"Johannsen","year":"2020","journal-title":"Neuropediatrics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mus.27217","article-title":"Laboratory Monitoring of Nusinersen Safety","volume":"63","author":"Goedeker","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e202868","DOI":"10.1001\/jamapediatrics.2020.2868","article-title":"Patient-Reported Outcomes in Pediatric Oncology: The Patient Voice as a Gold Standard","volume":"174","author":"Leahy","year":"2020","journal-title":"JAMA Pediatrics"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/8\/7\/604\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:10Z","timestamp":1760164270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/8\/7\/604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["children8070604"],"URL":"https:\/\/doi.org\/10.3390\/children8070604","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]}}}